"Complete Response" Transparency Could Spur Better Applications - Jenkins
This article was originally published in The Tan Sheet
Executive Summary
Office of New Drugs Director John Jenkins sees a possible side benefit for FDA of more efficient drug approval processes should the agency's transparency initiative lead to the public release of "complete response" letters
You may also be interested in...
FDA Transparency Has No Clear Path To Releasing Documents - Woodcock
The possible release of FDA's voluminous documents is one of the more challenging aspects - both in policies and resources - of the agency's effort to make its operations and decisions more open to the public, FDA's Janet Woodcock says
FDA Transparency Has No Clear Path To Releasing Documents - Woodcock
The possible release of FDA's voluminous documents is one of the more challenging aspects - both in policies and resources - of the agency's effort to make its operations and decisions more open to the public, FDA's Janet Woodcock says
FDA Transparency Has No Clear Path To Releasing Documents - Woodcock
The possible release of FDA's voluminous documents is one of the more challenging aspects - both in policies and resources - of the agency's effort to make its operations and decisions more open to the public, FDA's Janet Woodcock says